key: cord-1004141-9v8ksjbt
authors: Hans, Lucia; Steegen, Kim; Ketseoglou, Irene; Mahlumba, Zukiswa; Cassim, Naseem; Wiggill, Tracey; Venter, WD Francois; Stevens, Wendy
title: Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory
date: 2021-06-15
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.06.019
sha: 9707477c68076bf9b2c701a2ea4d051d0db925ad
doc_id: 1004141
cord_uid: 9v8ksjbt

Africa’s readiness to the respond to the SARS-COV-2 pandemic was tested due to reliance on rapid turn-around-time of polymerase chain reaction results for clinical management, isolation and quarantine decisions. The HIV Molecular Laboratory in Johannesburg, South Africa is one of the largest automated HIV molecular laboratories worldwide, performing 1.2 million tests annually. Despite its extensive molecular capacity and experience in managing high volumes acquired from a large HIV program, significant challenges were encountered during its rapid transition to largescale SARS-CoV-2 testing. Here, we describe the strategies employed to manage challenges related to policy, staff, introduction of new assays and workflow efficiencies, and to mitigate the risks of reprioritization of resources on routine HIV tests, that resulted in a 50% improvement in SARS-COV-2 turn-around-time during the first wave peak during which approximately 25 000 samples were tested per month, and further improvement during the second wave, with 91% within targeted turn-around-time.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. community transmission increased, staff infections rose and severe shortages were experienced due to self-isolation and quarantine. As a result, all levels of staff, including managers, were temporarily reassigned to SARS-CoV-2 bench duties. Staff from nonmolecular laboratories were recruited and utilised according to their skill sets. Rosters subsequently needed rapid revision but staff, now familiar with testing, adapted at short notice. The employment of temporary staff two months into the peak coincided with a matured workflow and reduction in staff anxiety permitting a seamless move to a 24-hour SARS-CoV-2 service.

The provision of a safe work environment was a priority. Immediate SARS-CoV-2 safety training was provided and protocols introduced, including designated testing areas. Refresher safety training occurred whenever needed, particularly when inconsistent use of nonpharmaceutical interventions within and outside the testing space became apparent.

Introducing new assays into the laboratory was facilitated by using existing equipment.

Authorization (FDA-EUA) (FDA, 2017) under time constraints, without the availability of standardised protocols which are routinely used in molecular evaluations, local authority guidelines for testing and suitable testing material was difficult early in the pandemic. The laboratory validated the cobas® SARS-CoV-2 Qualitative assay (cobas® assay) (Roche, 2020) and the Abbott RealTime SARS-CoV-2 (m2000 assay) (Abbott, 2020 ) shortly after receiving FDA-EUA. The lack of detailed manufacturer-led validations and the abbreviated performance review by the FDA left laboratories to resolve problems that would ordinarily have been resolved prior to market entry, e.g., determination of lower limit of detection (LoD) using copies/mL for the cobas® assay. The cobas® assay evaluation was hindered by a lack of testing material; mainly clinical samples with low level detectable viral RNA, and locally produced reference material that contained the DNA sequence to which the Target 2 J o u r n a l P r e -p r o o f probe (E gene) of assay bound but not Target 1 (ORF 1a/b gene) and for which the viral load had not been quantified.

Internationally peer-reviewed HIV (WHO, 2017) and local respiratory validation protocols were adapted for the cobas® assay. Clinical performance had to be evaluated comparing new assays due to the lack of a SARS-CoV-2 molecular reference assay and positive clinical specimens were diluted to verify clinical accuracy and sensitivity at lower levels of detectable viral RNA. While precision was verified for Target 2 only and LoD was partially verified for the cobas® assay using the local reference material, these results were adequate for conditional approval by the NHLS Virology Expert Committee, pending further evaluation when material became available. Subsequently, well characterised commercial material was used to complete the LoD and precision analyses, which proved to be significant when determining whether variants, including the "South African" B.1.351 variant, could be detected. The m2000 validation included more clinical and analytical data at the outset.

However, complex analyses were required when comparing results of the two assays particularly when determining clinical sensitivity at lower levels of viral RNA because of differing combinations of PCR targets and cycle threshold (Ct) calculation algorithms. The m2000 assay combined E and N gene target was found to be, on average, 10 Cts lower than the cobas® assay Target 2. Later, acceptable EQA results confirmed the reliability of both assays.

The complexity of pre-and post-analytical workflow of large volumes of specimens is often overlooked. This was demonstrated more clearly during this epidemic. In contrast to the automated HIVVL workflow which requires minimal hands-on time, SARS-CoV-2 tests required manual preparation, encompassing physical inspection of samples, labelling of additional tubes and aliquotting of swabs received in medium, or cutting of and immersing dry swabs into fluid matrix, followed by mixing and aliquotting, then manual J o u r n a l P r e -p r o o f loading/unloading of the instruments. Following a comprehensive analysis of the new workflow, staff adapted to the unfamiliar process by introducing simple measures like standardizing sample preparation procedures between different assays and using excel spreadsheets to streamline processes from sample receipt to storage. Remote access to the laboratory information system and instrument software enabled rapid release of results, cataloging of residual samples and rapid retrieval of invalid samples for repeat testing, successfully increasing the percentage of samples reported within the acceptable TAT of 48 hours from collection.

The laboratory started performing SARS-CoV-2 testing in April 2020 overlapping with the highly restrictive level 5 lockdown, during which approximately 97% of HIVVL and 50% of SARS-CoV-2 tests were reported within TAT. This was probably due to a lockdown-related drop in expected HIVVL and relatively low SARS-CoV-2 test requests (Figure 1 ). After transitioning to the less restrictive level 4 lockdown in May 2020, TAT dropped to 14% and 67% for SARS-CoV-2 and HIVVL respectively, as sample volumes for both tests increased substantially and reagent supply was unstable. The introduction of the improvement strategies resulted in an increase to 50% within TAT for SARS-CoV-2 tests during the peak month of July 2020 when 28 613 samples were tested and reaching >90% as the first wave subsided.

With the arrival of the second wave coinciding with the Christmas vacation period, TAT dropped to 52% in December when there were planned staff absences, the relocation of some temporary staff and numerous out of province referrals. The rapid redeployment of staff, stable supply of reagents and continuous use of the improvement measures lead to a further improvement during the January 2021 peak of the second wave compared to the first wave, with 81% within TAT. volumes for 2020 and 2021. Percentages within turnaround time (TAT) for SARS-CoV-2 and HIV viral load (HIVVL) displayed an upward trend from June 2021 and after July 2021, respectively. The drop in HIVVL percentage within TAT in November 2021 was due to instrument breakdowns. The second wave started during mid-December with the January 2021 volumes comparable to the July 2021 peak. HIVVL was significantly impacted by supplier reagent and consumable shortages as well as unplanned leave due to non-SARS related illness and family bereavements in January 2021.

Emergency Use Authorization of medical products and related authorities: guidance for industry and other stakeholders

cobas® SARS-CoV-2 Qualitative assay for use on the cobas® 6800/8800 Systems 09107991700-01EN Doc

World Health Organization. PQDx_215 Protocol for the laboratory evaluation of nucleic based HIV viral load testing technologies WHO

South Africa needs 'hundreds of thousands' of COVID-19 tests -Health Minister -CNBC Africa

This experience has challenged our team but we responded effectively with remarkable agility and resourcefulness. High-throughput labs are well-suited for pandemics and will serve us well in future events. Word count = 1105 The authors declare that they have no known conflicts interest that could have appeared to influence the work reported in this paper.The authors did not receive funding for this work.Ethics approval was obtained from the Human Research Ethics Committee of the University of the Witwatersrand.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.J o u r n a l P r e -p r o o f